Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SULFASALAZINE

All products: general benefit

PMS-Sulfasalazine-E.C. · DIN 00598488 · 500mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Sulfasalazine-E.C. · DIN 00598488 Manufacturer: Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 1984-12-31 · brand PMS-SULFASALAZINE-E.C. TAB 500MG · ATC A07EC01 SULFASALAZINE · form Tablet (enteric-coated) · route Oral · ingredients SULFASALAZINE 500 MG · company Delhar canada ltd. · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Sulfasalazine-E.C.: Formulary list price $0.3863/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3863 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5864 · Verify on the e-Formulary ↗ (DIN 00598488)

Source record
DIN 00598488: PMS-Sulfasalazine-E.C. Raw flags: sec3=Y Item: 082400006; group id 122; item number 0205; lccId None; manufacturer id PMS Source form: Ent Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.3863; ministry $0.3863 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00598488 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5864
Interchangeable products
Salazopyrin EN-TABS 500 MG · DIN 02064472 · $0.3863
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:24 Sulfonamides) and how they are covered
No products matched this class search: “08:24”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: active rheumatoid arthritis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LEFLUNOMIDE, PENICILLAMINE CYCLOSPORINE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (8) Rheumatoid Arthritis NEORAL capsules and oral solution (cyclosporine) are also indicated for the treatment of severe active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents are inappropriate or ineffective. PM: https://pdf.hres.ca/dpd_pm/00085584.PDF; date 2026-07-30; DIN 02150662; fetched 2026-09-10 Product monograph LEFLUNOMIDE · General benefit ARAVA is indicated in adults for the treatment of active rheumatoid arthritis. 1.1 Pediatrics The use in patients less than 18 years of age is contraindicated. 1.2 Geriatrics No dosage adjustment is needed in patients over 65 years of age. PM: https://pdf.hres.ca/dpd_pm/00083555.PDF; date not captured; DIN 02241888; fetched 2026-09-10 Product monograph PENICILLAMINE · General benefit INDICATIONS AND CLINICAL USE CUPRIMINE (penicillamine capsules, USP) is indicated for:  treatment of Wilson's disease  chronic lead poisoning  cystinuria, and  In patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. PM: https://pdf.hres.ca/dpd_pm/00054287.PDF; date not captured; DIN 00016055; fetched 2026-09-10 Product monograph TACROLIMUS · Limited Use, codes 173 (10), Limited Use, codes 410 (8), Limited Use, codes 383 (2), Limited Use, codes 590 (3) Rheumatoid Arthritis Prograf (tacrolimus immediate-release capsules, USP) is indicated for: • treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti-rheumatic drug (DMARD) therapy is ineffective or inappropriate. PM: https://pdf.hres.ca/dpd_pm/00082912.PDF; date 2025-12-17; DIN 02175983; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE pms-SULFASALAZINE (sulfasalazine) and pms-SULFASALAZINE-E.C. (sulfasalazine delayed-release tablets)) are indicated as an adjunctive therapy in the treatment of severe ulcerative colitis, proctitis or distal ulcerative colitis and Crohn's disease. It is especially useful for chronic administration. pms-SULFASALAZINE-E.C. is also indicated for the treatment of active rheumatoid arthritis, when treatment with an adequate conventional first line therapy has failed. https://pdf.hres.ca/dpd_pm/00056638.PDF PM date: April 30, 2020 Source product: PMS-SULFASALAZINE 500MG/TAB USP; DIN 00598461; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.